EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 547 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 What Is Intuitive Eating and How Can It Help During Cancer? January 31, 2023 Drug Combo JAKs Up Immunotherapy in Two Clinical Trials August 8, 2024 OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 Load more HOT NEWS Is there a future without Pap testing? FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... New on NCI’s Websites for October 2019
